News & Views

Filter by:

  • Chronic traumatic encephalopathy (CTE) is presumed to be associated with a clinical condition termed traumatic encephalopathy syndrome (TES). A new set of research diagnostic criteria for TES might be an improvement over previous guidelines, but many questions surrounding the putative link between head impacts, CTE neuropathology and neurobehavioural symptoms remain unanswered.

    • C. Munro Cullum
    • Christian LoBue
    News & Views
  • Biomarkers that predict conversion from isolated REM sleep behaviour disorder to Parkinson disease are urgently needed. A new study finds that detection of misfolded α-synuclein in the cerebrospinal fluid is a good marker of conversion risk, but an inability to predict the timeline of progression might limit its utility.

    • Sandrina Weber
    • Brit Mollenhauer
    News & Views
  • Apolipoprotein E (APOE) is the most abundant apolipoprotein in the brain, where it is primarily expressed and secreted by astrocytes and microglia. APOE seems to exert immunomodulatory effects in an isoform-dependent way, and a new study indicates that the APOE isoform dictates the glycosylation state and secretion of this apolipoprotein.

    • Philip Hasel
    • Shane A. Liddelow
    News & Views
  • A recent report in Nature Cancer proposes that glioblastoma can be stratified into four functional subgroups on the basis of pathway inference from single-cell or bulk gene expression data. The analysis disclosed a pathway-based subgroup of glioblastoma that depends on oxidative phosphorylation and could potentially be targeted with mitochondrial metabolism inhibitors.

    • Tobias Weiss
    • Michael Weller
    News & Views
  • A recent study reports an improvement in migraine symptoms during a COVID-19 lockdown in the Netherlands. The findings suggest that lifestyle changes can substantially alter the course of migraine, opening the door for greater use of behavioural interventions alongside existing pharmacological therapies.

    • Licia Grazzi
    • Paul Rizzoli
    News & Views
  • Assessment of the long-term effectiveness of disease-modifying therapies in multiple sclerosis is plagued by methodological issues, but statistical methods continue to evolve. Use of a novel approach has highlighted the importance of accounting for cumulative exposure to disease-modifying therapies when assessing the long-term effects of treatment on disability accumulation.

    • Maria Trojano
    • Pietro Iaffaldano
    News & Views
  • Although common, post-traumatic headache remains poorly understood and poorly treated. New data have implicated calcitonin gene-related peptide and the trigeminovascular system in this disorder, opening up new avenues for research into its pathophysiology and treatment.

    • Dimos D. Mitsikostas
    • Michael A. Moskowitz
    News & Views
  • A genome-wide association study has identified the first risk factors for sporadic prion disease other than mutations of PRNP, which encodes prion protein. These hits could open up new fronts in prion biology, risk prediction, and drug development.

    • Sonia M. Vallabh
    • Eric Vallabh Minikel
    News & Views
  • B cell-depleting agents are emerging as important disease-modifying drugs for multiple sclerosis, but their effectiveness in relation to established treatments remains uncertain. To cast light on this issue, several studies have provided head-to-head comparisons of the anti-CD20 antibody rituximab with natalizumab, fingolimod and dimethyl fumarate in patients with multiple sclerosis.

    • Tomas Kalincik
    • Maria Pia Sormani
    News & Views
  • With the advent of disease-modifying therapies for spinal muscular atrophy, prenatal and extra-neural alterations associated with the condition have garnered increasing attention as potential determinants of the therapeutic window and efficacy of novel drugs. Two recent studies highlight the impact of spinal muscular atrophy on prenatal bone and organ development.

    • Irene Faravelli
    • Stefania Corti
    News & Views
  • A new meta-analysis of placebo-controlled trials of calcitonin gene-related peptide (CGRP) antibodies for migraine has shown that the direct biological effects of these treatments beyond the effects of placebo are modest, raising questions about how the ‘true value’ of these and other drugs are assessed.

    • Elizabeth W. Loder
    • Brian McGeeney
    News & Views
  • Neurological soft signs (NSS) are minor motor and sensory changes that accompany the typical psychopathological symptoms and neuropsychological deficits that manifest in the early stages of schizophrenia. A new study provides evidence that NSS in early schizophrenia predict the long-term clinical outcomes of this condition.

    • Johannes Schröder
    • Pablo Toro
    News & Views
  • The Nigerian Parkinson Disease registry is the first published national Parkinson disease registry in sub-Saharan Africa. Though the clinical data and number of participants are currently limited in comparison with European, North American and Asian equivalents, this registry represents a valuable resource for the field.

    • Soraya Bardien
    • Jonathan Carr
    News & Views
  • A recent study describes the yield and clinical utility of epilepsy gene panel testing in a cohort of adults with epilepsy and intellectual disability. These findings are similar to those in children with developmental epileptic encephalopathies and support the utility of testing in this subgroup of adults with epilepsy.

    • Ruth Ottman
    • Annapurna Poduri
    News & Views
  • A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive benefits; however, limitations of the original studies, including brief duration, restricted assessment and failure to account for baseline cognitive impairment, might limit the interpretation of the findings.

    • Maria Pia Amato
    • Lauren B. Krupp
    News & Views
  • Genome-wide association studies (GWASs) have identified multiple loci associated with Parkinson disease; however, most of these studies were carried out in North American or European populations. A large-scale GWAS in East Asian populations has now identified two novel Parkinson disease-associated loci, which could improve risk prediction in Asian individuals.

    • Ruey-Meei Wu
    • Matthew J. Farrer
    News & Views
  • Combined assessment of latest-generation molecular and MRI biomarkers has provided insight into the dynamics of brain volume loss after immunoablative autologous haematopoietic stem cell transplantation in multiple sclerosis, shedding light on the transient neurotoxic effects of this procedure.

    • Nicola De Stefano
    • Maria Pia Sormani
    News & Views
  • The COVID-19 pandemic has added an additional layer of complexity to endovascular treatment (EVT) for acute ischaemic stroke. Drawing on recently published guidelines, this article provides a conceptual framework for EVT in the COVID-19 era, outlining key principles for ensuring safe and timely EVT while minimizing the risk of infectious exposure for health-care workers and patients.

    • Johanna M. Ospel
    • Mayank Goyal
    News & Views
  • A recently published consensus statement from the European Academy of Neurology provides new guidance on the diagnosis and management of monogenic cerebral small vessel diseases. Despite a lack of high-quality evidence, the recommendations are likely to be useful to all clinicians involved in the diagnosis and treatment of these conditions.

    • David J. Werring
    • David S. Lynch
    News & Views
  • Disorders of consciousness (DOCs), including vegetative and minimally conscious states, represent a financial, medical and ethical conundrum. Recently published guidelines for the diagnosis, prognosis and treatment of DOCs should lead us to reconsider our management strategies for these challenging disorders.

    • Caroline Schnakers
    • Martin M. Monti
    News & Views